MIL · CPR.MI
Davide Campari-Milano N.V.
€6.21+€0.09 (+1.44%)
Davide Campari-Milano N.V.’s quoted price sits in the upper half of its reported 52-week range, 8.89% below the high.
Loading market information…
MIL · FF.MI · EUR
Stock price, dividends, earnings
Quote as of Oct 30, 2026, 03:11 PM UTC. Cached market data; not a live quote.
One-year closing-price history · EUR. Historical prices are not a forecast.
Fine Foods & Pharmaceuticals N.T.M. S.p.A.’s quoted price sits in the lower half of its reported 52-week range, 47.23% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
THE INCOME SIDE
Fine Foods & Pharmaceuticals N.T.M. S.p.A.’s forward annual dividend is €0.16 per share, paid annual. The forward yield is 2.55% at the quoted price. Future payments can change.
Historical amounts are adjusted for stock splits. Understand ex-dividend and payment dates →
BEHIND THE RESULTS
Fine Foods & Pharmaceuticals N.T.M. S.p.A.’s next earnings report is currently expected on Nov 10, 2026. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow Fine Foods & Pharmaceuticals N.T.M. S.p.A.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Fine Foods & Pharmaceuticals N.T.M. S.p.A. functions as a contract development and manufacturing organization (CDMO), specializing in the creation of various oral solid forms for the pharmaceutical and nutraceutical sectors. Its pharmaceutical offerings include items such as powders, granules, capsules, standard and film-coated tablets, effervescent granules, and hard gelatine capsules. For the nutraceutical market, the company produces soluble, effervescent, and chewable tablets, fast-melting/sublingual tablets, film-coated tablets, and hard gelatine capsules, alongside soluble and effervescent powders and granules. These nutraceutical products are designed to support a wide range of health needs, encompassing areas like probiotics, multivitamins and minerals, immune system function, sleep and relaxation, gastrointestinal and circulatory health, osteoarticular and urinary systems, women's health, beauty, healthy aging, and mental wellbeing. In addition to its core CDMO services, the company also manufactures and sells a diverse array of cosmetic products, covering hair care, skin care, liquid personal hygiene items, oral hygiene products, deodorants, alcohol-based perfumery, bath and shower gels, shampoos and conditioners, shaping waxes, mouthwashes, creams, gels, and toothpastes. Furthermore, they supply medical surgical aids and devices, various antiseptics for intact skin, hand sanitizers, pre-injection solutions, hydroalcoholic surface cleaners, and iodine. Their product line also extends to orthodontic cleaning tablets, disinfectants, and decongestant nasal sprays. Established in 1984, the company is headquartered in Verdellino, Italy.
Latest available per-share figures in EUR. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 03:28 PM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
Completed calendar years and any current-year payments shown separately. Current-year totals are incomplete until all payments are made.
See annual income at the current dividend rate.
Assumes the annual dividend stays unchanged. Payments follow the company’s schedule. Excludes taxes, fees and currency changes.
| Q4 2024 | Mar 13, 2025 | €0.06 | €66.80M-1.76% vs estimate |
|---|
| Q3 2024 | Nov 14, 2024 | €0.09 | €54.40M-20.0% vs estimate |
|---|
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
€6.21+€0.09 (+1.44%)
Davide Campari-Milano N.V.’s quoted price sits in the upper half of its reported 52-week range, 8.89% below the high.
€5.13-€0.07 (-1.35%)
MARR S.p.A.’s quoted price sits in the lower half of its reported 52-week range, 47.06% below the high.
€14.32-€0.24 (-1.65%)
Orsero S.p.A.’s quoted price sits in the lower half of its reported 52-week range, 29.46% below the high.
€10.80+€0.05 (+0.47%)
Valsoia S.p.A.’s quoted price sits in the upper half of its reported 52-week range, 3.14% below the high.
€3.89+€0.01 (+0.26%)
Centrale del Latte d'Italia S.p.A.’s quoted price sits in the lower half of its reported 52-week range, 34.07% below the high.
€1.31+€0.06 (+4.8%)
Giocamondo Study S.r.l.’s quoted price sits in the lower half of its reported 52-week range, 34.17% below the high.
€0.40€0.00 (0.0%)
Compagnia dei Caraibi S.p.A.’s quoted price sits in the lower half of its reported 52-week range, 32.37% below the high.
€0.76-€0.02 (-2.56%)
Alfio Bardolla Training Group S.p.A.’s quoted price sits in the lower half of its reported 52-week range, 61.03% below the high.
